4.6 Article

Pharmacogenetics May Prevent Psychotropic Adverse Events in Autism Spectrum Disorder: An Observational Pilot Study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Pharmacology & Pharmacy

Contrasting ABCB1 pharmacogenetics and psychotropic responses in child and adolescent psychiatry: a case comparison

Pragya Kalla et al.

Summary: This report focuses on the ABCB1 gene in child psychiatry and its role in drug efficacy and side effects. The study compares two pediatric patients with different functionality of the ABCB1 gene and finds that these differences may affect the concentration of antidepressants in the brain and subsequently the therapeutic response. Further research is needed to understand the involvement of the blood-brain barrier and the P-glycoprotein transporter in psychiatric diseases.

PHARMACOGENOMICS (2023)

Review Psychiatry

Dopamine in Autism Spectrum Disorders-Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment

Vanja Mandic-Maravic et al.

Summary: Autism spectrum disorders (ASD) are characterized by impairment in social communication and repetitive behaviors. The causes of ASD are complex, involving both genetic and environmental factors. Current treatments only target the non-specific symptoms, and no specific treatment for the core symptoms of ASD has been developed.

FRONTIERS IN PSYCHIATRY (2022)

Review Medicine, Research & Experimental

Cellular and molecular mechanisms underlying autism spectrum disorders and associated comorbidities: A pathophysiological review

Hussain Al Dera

Summary: This paper reviews the major molecular mechanisms responsible for the clinical symptoms seen in people with ASD, including genetic factors, neuroinflammation, neurotransmitter signaling, and calcium signaling. It also covers the molecular mechanisms underlying epileptic seizures and sleep disorders.

BIOMEDICINE & PHARMACOTHERAPY (2022)

Review Pharmacology & Pharmacy

Pharmacogenomics in clinical practice to prevent risperidone-induced hyperprolactinemia in autism spectrum disorder

Mohitosh Biswas et al.

Summary: ASD is a global challenge that significantly disrupts family and social life. There is evidence suggesting the association between pharmacokinetic and pharmacodynamic gene variants and risperidone-induced hyperprolactinemia in ASD. Additionally, factors such as risperidone dosage, duration, and drug-drug interactions may also contribute to elevated prolactin levels. Implementing risperidone pharmacogenomics into clinical practice faces difficulties such as reimbursement and knowledge of healthcare providers. However, the development of national and international pharmacogenomics-based dosing guidelines for risperidone may advance precision medicine for ASD.

PHARMACOGENOMICS (2022)

Review Medicine, General & Internal

Management of psychotropic medications in adults with intellectual disability: a scoping review

Ashley Costello et al.

Summary: This scoping review provides an overview of research on medication use and practices in adults with intellectual disability taking psychotropic medications for challenging behaviors. The findings suggest that high dosing of psychotropic medications without a clear clinical indication may worsen symptoms. While psychotropics can help manage challenging behaviors, reducing or discontinuing their use may also be necessary. The study designs were often pragmatic, resulting in small sample sizes and heterogeneity in medication doses and combinations. Multidisciplinary teams, guidelines, medication reviews, staff training, and involving caregivers in decision-making were recommended to optimize psychotropic use.

ANNALS OF MEDICINE (2022)

Review Psychiatry

Pharmacogenomic Studies in Intellectual Disabilities and Autism Spectrum Disorder: A Systematic Review: etudes Pharmacogenomiques en Deficiences Intellectuelles et Trouble du Spectre de L'autisme: Une Revue Systematique

Kazunari Yoshida et al.

Summary: There is limited data available on pharmacogenomic studies in individuals with ASD/ID, with most studies focusing on children/adolescents and few on adults. Candidate gene studies on treatment response and adverse effects suggest some associations between certain genes and treatment outcomes, but further research is needed to confirm these links.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2021)

Article Neurosciences

Neuropsychological Profile, Emotional/Behavioral Problems, and Parental Stress in Children with Neurodevelopmental Disorders

Francesca Felicia Operto et al.

Summary: This study aimed to compare children with Autism Spectrum Disorder Level 1/High functioning, Specific Learning Disorders, and Attention Deficit/Hyperactivity Disorder in terms of neuropsychological profile, emotional-behavioral problems, and parental stress. Significant differences were found between the three groups, highlighting specific deficiencies compared to the control group in cognitive profile, behavioral and emotional problems, and parental stress. The findings help to define the cognitive, behavioral, and emotional characteristics of these children and the parental stress of their parents.

BRAIN SCIENCES (2021)

Article Medicine, Research & Experimental

Acceptability, Feasibility, and Utility of Integrating Pharmacogenetic Testing into a Child Psychiatry Clinic

Karla Claudio-Campos et al.

Summary: Pharmacogenetic testing is seen as useful in identifying patients at higher risk and medication selection, but challenges with test utility in clinical decision making were noted in this study. While there were no differences in clinical endpoints within 13 weeks, there were potential issues with higher side effect scores observed among certain CYP2D6 metabolizers. More research is needed to address these concerns in real-world clinical settings.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Article Genetics & Heredity

Gender based differences, pharmacogenetics and adverse events in chronic pain management

Beatriz Planelles et al.

PHARMACOGENOMICS JOURNAL (2020)

Article Behavioral Sciences

The potential impact of COMT gene variants on dopamine regulation and phenotypic traits of ASD patients

Nora N. Esmaiel et al.

BEHAVIOURAL BRAIN RESEARCH (2020)

Editorial Material Genetics & Heredity

Pharmacogenomics and Personalized Medicine

Erika Cecchin et al.

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Article Psychiatry

Modulation of brain activation during executive functioning in autism with citalopram

Robert H. Wichers et al.

TRANSLATIONAL PSYCHIATRY (2019)

Article Psychology, Developmental

BDNF 196 G/A and COMT Val158Met Polymorphisms and Susceptibility to ADHD: A Meta-Analysis

Young Ho Lee et al.

JOURNAL OF ATTENTION DISORDERS (2018)

Review Biochemistry & Molecular Biology

Classics in Chemical Neuroscience: Risperidone

Trevor C. Chopko et al.

ACS CHEMICAL NEUROSCIENCE (2018)

Article Pharmacology & Pharmacy

Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants

Miriam Saiz-Rodriguez et al.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2018)

Article Psychology, Clinical

Effects of acute beta-adrenergic antagonism on verbal problem solving in autism spectrum disorder and exploration of treatment response markers

Rachel M. Zamzow et al.

JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY (2017)

Article Biochemistry & Molecular Biology

GeneAnalytics Pathway Analysis and Genetic Overlap among Autism Spectrum Disorder, Bipolar Disorder and Schizophrenia

Naveen S. Khanzada et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)

Review Pharmacology & Pharmacy

Pharmacogenomics of autism spectrum disorder

Jacob T. Brown et al.

PHARMACOGENOMICS (2017)

Article Psychiatry

Restoring effects of oxytocin on the attentional preference for faces in autism

M. Kanat et al.

TRANSLATIONAL PSYCHIATRY (2017)

Editorial Material Pharmacology & Pharmacy

What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?

Jose de Leon et al.

EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2016)

Review Pharmacology & Pharmacy

Psychopharmacological interventions in autism spectrum disorder

Robert E. Accordino et al.

EXPERT OPINION ON PHARMACOTHERAPY (2016)

Article Psychology, Developmental

The health status of adults on the autism spectrum

Lisa A. Croen et al.

AUTISM (2015)

Article Psychiatry

Adjustment of the UKU Side Effect Rating Scale for adults with intellectual disabilities. A pilot study

Anne Louise Tveter et al.

ADVANCES IN MENTAL HEALTH AND INTELLECTUAL DISABILITIES (2014)

Review Psychiatry

D2 Receptor Genetic Variation and Clinical Response to Antipsychotic Drug Treatment: A Meta-Analysis

Jian-Ping Zhang et al.

AMERICAN JOURNAL OF PSYCHIATRY (2010)

Article Pharmacology & Pharmacy

The role of CYP2D6 and ABCB1 pharmacogenetics in drug-na⟨ve patients with first-episode schizophrenia treated with risperidone

Nikolina Jovanovic et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)

Review Pharmacology & Pharmacy

Emerging drugs for the treatment of symptoms associated with autism spectrum disorders

Logan K. Wink et al.

EXPERT OPINION ON EMERGING DRUGS (2010)

Article Psychology, Developmental

Association of COMT (Val158Met) and BDNF (Val66Met) Gene Polymorphisms with Anxiety, ADHD and Tics in Children with Autism Spectrum Disorder

Kenneth D. Gadow et al.

JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS (2009)

Article Psychiatry

Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting

Malin Alenius et al.

JOURNAL OF PSYCHIATRIC RESEARCH (2008)

Review Neurosciences

Clinical applications of pharmacogenetics in psychiatry

S Staddon et al.

PSYCHOPHARMACOLOGY (2002)